Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist developed for obesity and metabolic disorders. It improves glucose metabolism, increases satiety, reduces food intake, and promotes significant weight loss. Clinical studies have shown strong efficacy in reducing body weight and visceral fat, with ongoing trials exploring long-term cardiovascular and endocrine benefits. Developed by Innovent Biologics, it has shown promising results in early clinical trials in China

• GLP-1 receptor agonism
• Glucagon receptor agonism
• Enhances insulin secretion in a glucose-dependent manner
• Suppresses postprandial glucagon secretion
• Delays gastric emptying and promotes satiety

• unit: mg

  low dose: 2

  frequency: Weekly

  high dose: 9

  standard dose: 6

  administration route: Subcutaneous (SQ)

• Weekly injection; titration phase from 4 mg to 6–9 mg based on tolerance. Continuous use protocol under clinical supervision. Monitor glucose, lipids, renal function, and thyroid markers periodically.

common: ["GI effects (nausea, vomiting, diarrhea, constipation) — typically mild-moderate, diminishing over time","Gradual dose titration significantly improves tolerability"]

sequence: H-His-Asp-Tyr-Tyr-Ser-Tyr-Gly-Leu-His-Gln-Lys-Thr-Lys-Pro-Arg-Tyr-NH2

half life: Approximately 8–12 hours; supports once-weekly use

degradation: Metabolized primarily via proteolysis and renal excretion

molecular weight: 4679.44

molecular formula: C209H344N55O67

tissue specificity: Targets GLP-1 and glucagon receptors in brain, liver, pancreas, and adipose tissue

• Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.clinicalPMID 40421736 ↗
• Safety and efficacy of GLP-1 and glucagon receptor dual agonist mazdutide (IBI362).clinicalPMID 36247927 ↗